Introduction. Hyperprolactinemia represents a supraphysiological secretion of prolactin. In clinical practice, it is the most frequently encountered anterior pituitary disorder. However, its real prevalence is little known in Africa. The purpose of this study is to list all cases of hyperprolactinemia over the past four years and to make an inventory of the various etiologies found and their management. Methodology. This is a cross-sectional descriptive study on the files of patients who came for consultation in the internal medicine and endocrinology department with hyperprolactinemia retrospectively collected from January 2017 to December 2020. Included were patients followed or whose the diagnosis of hyperprolactinemia was established in endocrinological consultation during the study period. Results. This study recorded 26 cases of hyperprolactinemia. The female sex represented 73.08% (sex ratio M/F 0.37) and the average age was 33.92 years. The 40 - 50 age group was the most represented with 30.77%. In women, galactorrhea accounted for 73.07%, amenorrhea 57.69% of clinical pictures and infertility 23.08%. In men, infertility accounted for 7.69% of presentations, gynecomastia 11.54% and erectile dysfunction 15.38%. The duration of evolution of the signs was 4 months in 23.08% of the patients. The mean prolactinemia was 702.58 ng/ml. CT was performed in 80.85% of patients. The main etiologies were pituitary adenomas (77%). All our patients were treated with dopaminergic agonists. Cabergoline was prescribed in 77% of patients. The evolution was favorable in 96.25% of patients. Conclusion. Hyperprolactinemia is a pathology that exists in our regions. The main etiology remains pituitary adenomas and treatment with cabergoline.
References
[1]
Castinetti, F. and Brue, T. (2018) Hyperprolactinemie. Traité d’endocrinologie. Médecine-Sciences Flammarion, 938-942.
[2]
Dumazeau, O. (2009) Traitements médical et chirurgical des hyperprolactinemies. Thèse en Pharmacie, Université de Limoge, France, 215 p.
[3]
Paepegaey, A., Salenave, S., Kamenicky, P., Maione, L., Brailly-Tabard, S., Young, J., et al. (2017) Cabergoline Tapering is Almost Always Successful in Patients with Macroprolactinomas. Journal of the Endocrine Society, 1, 221-230 https://doi.org/10.1210/js.2017-00038
[4]
Soto-Pedre, E. (2017) The Epidemiology of Hyperprolactineamia over 20 Years in the Tayside Region of Scotland: The Prolactin Epidemiology, Audit and Research Study (PROLEARS). Clinical Endocrinology, 86, 60-67. https://doi.org/10.1111/cen.13156
[5]
N’guessan, K.B. and Lokrou, L.A. (2003) Les hyperprolactinémies en Côte d’Ivoire: étude d’une série de 94 cas observés au CHU de Treichville. Thèse en médecine université de cocody d’Abidjan, 85 p.
[6]
Seck, M. (2003) Hyperprolactinemie primaire. Thèse en medicine, Université Cheikh AntaDiop de Dakar, Dakar, 79 p.
[7]
Mariko, M. and Sidibé, A.T. (2017) Hyperprolactinémie à l’hôpital du Mali. Annales d’Endocrinologie, 78, 316-331. https://doi.org/10.1016/j.ando.2017.07.318
[8]
Azhar, A. (2019) Aetiologies of Hyperprolactinaemia, a Retrospective Analysis from a Tertiary Healthcare Centre. Sultan Qaboos University Medical Journal, 19, 129-134 https://doi.org/10.18295/squmj.2019.19.02.008
[9]
Etoga, E.M.C. (2020) Clinical Profile and Early Therapeutic Response to Cabergoline of Patients with Hyperprolactinemia in a Cameroonian Population. Pan African Medical Journal, 35, Article 2. https://doi.org/10.11604/pamj.2020.35.2.12883
[10]
Sedzro, K. (2020) Les adénomes hypophysaires Aspects épidémiologique, diagnostique, thérapeutique et évolutif au CHU Sylvanus Olympio de Lomé. Thèse en Médecine, Université de Lomé, Togo, 117 p.
[11]
Ma, M.S., Moumptala, S.R., Moussa, D., Brah, S., Maazou, M.L., Malam-Abdou, B., et al. (2018) Etiologie des hyperprolactinémies au Niger. Healthcare Scientists, 19, 57-60.
[12]
Smeeth, D.M., Kourouzidou, I., Duarte, R.R.R., Powell, T.R. and Thuret, S. (2021) Prolactin, Estradiol and Testosterone Differentially Impact Human Hippocampal Neurogenesis in an in Vitro Model. Neuroscience, 454, 15-39. https://doi.org/10.1016/j.neuroscience.2019.12.021
[13]
Nguenan, M. (2004) Pathologie Hypophysaire en Médecine Interne de Point G de Bamako. Thèse en médecine. Université de Mali, 135 p.
[14]
Nouedoui, C., Moukouri, E. and Juimo, A.G. (2000) Les adénomes à prolactine à Yaoundé: étude analytique de 36 cas consécutifs suivis dans le service de médecine interne de l’Hôpital de Yaoundé de 1990 à 1996. Clinique, 82, 111-114.
[15]
Abram, F., Linke, F. and Kalfon, A. (1998) Dysérection secondaire à une hyperprolactinémie. A propos de 13 cas. Basic and Clinical Andrology, 8, 537-541.
[16]
Vilar, L., Abucham, J., Albuquerque, J.L., Araujo, L.A., Azevedo, M.F., Boguszewski, C.L., et al. (2018) Controversial Issues in the Management of Hyperprolactinemia and Prolactinomas—An Overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Archives of Endocrinology and Metabolism, 62, 236-263. https://doi.org/10.20945/2359-3997000000032
[17]
Soto-Pedre, E., Newey, P.J., Bevan, J.S., Greig, N. and Leese, G.P. (2017) The Epidemiology of Hyperprolactinaemia over 20 Years in the Tayside Region of Scotland: The Prolactin Epidemiology, Audit and Research Study (PROLEARS). Clinical Endocrinology, 86, 60-67. https://doi.org/10.1111/cen.13156
[18]
Vilar, L., Freitas, M.C., Naves, L.A., Casulari, L.A., Azevedo, M., Montenegro Jr. R., et al. (2008) Diagnosis and Management of Hyperprolactinemia: Results of a Brazilian Multicenter Study with 1234 Patients. Journal of Endocrinological Investigation, 31, 436-744 https://doi.org/10.1007/BF03346388
[19]
Essais, O., Bouguerra, R. and HamzaouI, J. (2002) Efficacy and Safety of Bromocriptine in the Treatment of Macroprolactinomas. An Endocrinol (Paris), 63, 524-531
[20]
Wang, A.T., Mullan, R.J., Lane, M.A., Hazem, A., Prasad, C., Gathaiya, N.W., et al. (2012) Treatment of Hyperprolactinemia: A Systematic Review and Meta-Analysis. Systematic Reviews, 1, Article No. 33. https://doi.org/10.1186/2046-4053-1-33
[21]
Horvath, J., Fross, R.D., Kleiner-Fisman, G., Lerch, R., Stalder, H., Liaudat, S., et al. (2004) Severe Multivalvular Heart Disease: A New Complication of the Ergot Derivative Dopamine Agonists. Movement Disorders, 19, 656-662. https://doi.org/10.1002/mds.20201
[22]
Rascol, O., Pathak, A., Bagheri, H. and Montastruc, J.L. (2004) New Concerns about Old Drugs: Valvular Heart Disease on Ergot Derivative Dopamine Agonists as an Exemplary Situation of Pharmacovigilance. Movement Disorders, 19, 611-613. https://doi.org/10.1002/mds.20202
[23]
Motazedian, S., Babakhani, L., Fereshtehnejad, S.M. and Mojtahedi, K. (2010) A Comparison of Bromocriptine & Cabergoline on Fertility Outcome of Hyperprolactinemic Infertile Women Undergoing Intrauterine Insemination. Indian Journal of Medical Research, 131, 670-674.
[24]
Bahceci, M., Sismanoglu, A. and Ulug, U. (2010) Comparison of Cabergoline and Bromocriptine in Patients with Asymptomatic Incidental Hyperprolactinemia Undergoing ICSI-ET. Gynecological Endocrinology, 26, 505-508. https://doi.org/10.3109/09513591003632233
[25]
Lafeber, M., Stades, A.M.E., Valk, G.D., Cramer, M.J., van Berkhout, F.T. and Zelissen, P.M.J. (2010) Absence of Major Fibrotic Adverse Events in Hyperprolactinemic Patients Treated with Cabergoline. European Journal of Endocrinology, 162, 667-675. https://doi.org/10.1530/EJE-09-0989
[26]
Chen, H., Fu, J. and Huang, W. (2016) Dopamine Agonists for Preventing Future Miscarriage in Women with Idiopathic Hyperprolactinemiaand Recurrent Miscarriage History. Cochrane Database of Systematic Reviews, 7, Article No. CD008883. https://doi.org/10.1002/14651858.CD008883.pub2
[27]
Tan, T., Cabrita, I.Z., Hensman, D., Grogono, J., Dhillo, W.S. and Baynes, K.C. (2010) Assessment of Cardiac Valve Dysfunction in Patients Receiving Cabergoline Treatment for Hyperprolactinaemia. Clinical Endocrinology, 73, 369-374. https://doi.org/10.1111/j.1365-2265.2010.03827.x
